Skip to content
Screener

Ultragenyx Pharmaceutical RARE Cost Of Sales And Operating Expenses

Cost Of Sales And Operating Expenses at other companies

Kirby Corporation logo
Kirby CorporationKEX
$631.6M+12.1%
Intel logo
IntelINTC
$3.79B+14.6%
Intel logo
IntelINTC
$6.53B+12.3%
Home Depot logo
Home DepotHD
$4B+60.0%
Intel logo
IntelINTC
$7.85B+3.5%
Intel logo
IntelINTC
$471M-52.1%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.46B-9.2%
P/S3.4×-1.0×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept rare:CostOfSalesAndOperatingExpenses.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales34236452
Research and development167165354331
Selling, general and administrative8887176174
Total operating expenses289275594557
Loss from operations(75)(108)(244)(251)
Interest income561113
Non-cash interest expense on liabilities for sales of future royalties(22)(14)(43)(28)
Other income1212

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's cost of sales and operating expenses?
Ultragenyx Pharmaceutical (RARE) reported cost of sales and operating expenses of $289M in Q2 2026.
How has Ultragenyx Pharmaceutical's cost of sales and operating expenses changed year-over-year?
Ultragenyx Pharmaceutical's cost of sales and operating expenses increased by 5.1% year-over-year, from $275M to $289M.
What is the long-term trend for Ultragenyx Pharmaceutical's cost of sales and operating expenses?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's cost of sales and operating expenses has grown at a 13.3% compound annual growth rate (CAGR), from $733.14M to $1.21B.
What does cost of sales and operating expenses mean?
Cost Of Sales And Operating Expenses as reported by Ultragenyx Pharmaceutical Inc..

Ask your AI about Ultragenyx Pharmaceutical's cost of sales and operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude